Randomized Phase II Trial of All-Trans-Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Non–Small-Cell Lung Cancer

• Published in: Journal of clinical oncology Vol. 28; no. 21; pp. 3463 - 3471
• Main Authors: Arrieta, Oscar, González-De la Rosa, Claudia H, Aréchaga-Ocampo, Elena, Villanueva-Rodríguez, Geraldine, Cerón-Lizárraga, Tania L, Martínez-Barrera, Luis, Vázquez-Manríquez, María E, Ríos-Trejo, Miguel Angel, Alvarez-Avitia, Miguel A, Hernández-Pedro, Norma, Rojas-Marín, Carlos, De la Garza, Jaime
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 20.07.2010
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Cisplatin - administration & dosage; Double-Blind Method; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Male; Middle Aged; Paclitaxel - administration & dosage; Receptors, Retinoic Acid - analysis; Tretinoin - administration & dosage

This randomized phase II trial evaluated whether the combination of cisplatin and paclitaxel (PC) plus all-trans retinoic acid (ATRA) increases response rate (RR) and progression-free survival (PFS) in patients with advanced non-small-cell lung cancer (NSCLC) with an acceptable toxicity profile and...